All
The Week of May 6 in Review
The week of May 6 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.
Researchers Identify Potentially Druggable Targets in Acute Myeloid Leukemia
Acute myeloid leukemia (AML), the most common acute form of leukemia in adults, is potentially driven by at least one genetic mutation in nearly all cases.
Mechanism of Action: Cetuximab
Cetuximab is an epidermal growth factor receptor inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer.
Dacomitinib Shows Promising Activity in EGFR-Mutated and HER2-Mutated NSCLC
Nearly three-fourths of patients with previously untreated advanced NSCLC with specific mutations of EGFR experienced one full year of PFS when given the investigational therapeutic agent dacomitinib.
